Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABBDABF 47 OCF Yield % is 13.82 as of Jul. 14, 2026, which is 244% above its 10-year median of 4.02. GuruFocus rates BDABF with a GF Score™ of 47/100 and a GF Value™ of $14.73. The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Boule Diagnostics AB ranks better than 91.9% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Boule Diagnostics AB OCF Yield % Related Terms
Boule Diagnostics AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boule Diagnostics AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (BDABF) has a OCF Yield % of 13.82 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Boule Diagnostics AB and its competitors. This is 244% above median its historical median of 4.02. According to the industry distribution chart, Boule Diagnostics AB ranks #69 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 8.1%.
Is Boule Diagnostics AB's OCF Yield % too high?
Boule Diagnostics AB's current OCF Yield % of 13.82 is 244% above median its 10-year median of 4.02. The Medical Devices & Instruments industry median OCF Yield % is 1.72. Boule Diagnostics AB's value of 13.82 is 705.8% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #69 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #69 out of 852 companies for OCF Yield %. This places Boule Diagnostics AB in the top 8% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.72. Boule Diagnostics AB's value of 13.82 is 705.8% above this benchmark. While the company's 10-year median is 4.02 vs. the industry median of 1.72, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.72, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current OCF Yield % of 13.82 is 705.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current OCF Yield % is 13.82, which is 244% above median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (BDABF) has a current OCF Yield % of 13.82. The stock's GF Value™ is $14.73, compared to a current price of $7.84 — trading 46.8% below its estimated fair value. The current OCF Yield % is 13.82, which is 244% above median its 10-year median of 4.02 and 705.8% above the Medical Devices & Instruments industry median of 1.72. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Boule Diagnostics AB (BDABF), the current OCF Yield % is 13.82 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (BDABF) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of $7.84 is trading 46.8% below its estimated GF Value™ of $14.73.
Key valuation signals for BDABF:
OCF Yield %: 13.82 (244% above median its 10-year median of 4.02)
GF Value™: $14.73 vs. price of $7.84 (46.8% below fair value)
Industry Position: 705.8% above the Medical Devices & Instruments median (#69 of 852)
No single metric tells the full story. See the BDABF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for BDABF
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDABF has been successfully added to your 
